Screening for High-Risk Human Papillomavirus Reveals HPV52 and HPV58 among Pediatric and Adult Patient Saliva Samples.

Hunter Hinton, Lorena Herrera, Sofia Valenzuela, Katherine M Howard, Karl Kingsley
Author Information
  1. Hunter Hinton: Department of Advanced Education in Orthodontics, School of Dental Medicine, University of Nevada-Las Vegas, 1700 W. Charleston Boulevard, Las Vegas, NV 89106, USA.
  2. Lorena Herrera: Department of Clinical Sciences, School of Dental Medicine, University of Nevada-Las Vegas, 1700 W. Charleston Boulevard, Las Vegas, NV 89106, USA.
  3. Sofia Valenzuela: Department of Clinical Sciences, School of Dental Medicine, University of Nevada-Las Vegas, 1700 W. Charleston Boulevard, Las Vegas, NV 89106, USA.
  4. Katherine M Howard: Department of Biomedical Sciences, School of Dental Medicine, University of Nevada-Las Vegas, 1001 Shadow Lane Boulevard, Las Vegas, NV 89106, USA. ORCID
  5. Karl Kingsley: Department of Biomedical Sciences, School of Dental Medicine, University of Nevada-Las Vegas, 1001 Shadow Lane Boulevard, Las Vegas, NV 89106, USA. ORCID

Abstract

Previous research has demonstrated that the human papillomavirus (HPV) can infect a wide range of human tissues, including those within the oral cavity. High-risk oral HPV strains have been associated with the development and progression of oral cancers, including oral squamous cell carcinomas. Although many studies have examined the prevalence of the high-risk strains HPV16 and HPV18, far fewer have assessed the prevalence of other high-risk HPV strains. An approved study protocol was used to identify HPV52 and HPV58 among clinical samples ( = 87) from a saliva biorepository. Quantitative polymerase chain reaction (qPCR) and validated primers for HPV52 and HPV58 were used to facilitate this screening. This screening demonstrated that a total of = 4/45 or 8.9% of adult saliva samples harbored high-risk HPV52, and = 2/45 or 4.4% tested positive for high-risk HPV58. In addition, a total of = 6/42 or 14.3% of the pediatric saliva samples tested positive for high-risk HPV, including = 5/42 or 11.9% with HPV52 and = 3/42 or 7.1% for HPV58. These data demonstrate the presence of the high-risk oncogenic HPV52 and HPV58 strains among both adult and pediatric clinical patient samples. More detailed longitudinal research must be conducted to determine whether this prevalence may be increasing or decreasing over time. In addition, these data strongly support public health prevention efforts, such as knowledge and awareness of the nine-valent HPV vaccine covering additional high-risk strains, including HPV52 and HPV58.

Keywords

References

  1. J Family Med Prim Care. 2021 Jan;10(1):387-391 [PMID: 34017758]
  2. Prev Med. 2019 May;122:109-117 [PMID: 31078164]
  3. Expert Rev Vaccines. 2023 Jan-Dec;22(1):1168-1178 [PMID: 37990881]
  4. World J Oncol. 2020 Aug;11(4):173-181 [PMID: 32849958]
  5. Acad Pediatr. 2018 Mar;18(2S):S23-S27 [PMID: 29502633]
  6. Vaccines (Basel). 2022 Sep 02;10(9): [PMID: 36146530]
  7. Epidemiol Infect. 2017 Jul;145(10):1962-1982 [PMID: 28446260]
  8. BMC Cancer. 2018 Jun 27;18(1):696 [PMID: 29945565]
  9. J Natl Cancer Inst. 2015 Oct 14;108(1): [PMID: 26467666]
  10. Biofactors. 2019 Mar;45(2):101-117 [PMID: 30496635]
  11. J Clin Virol. 2010 Jul;48(3):198-201 [PMID: 20427229]
  12. Dent J (Basel). 2022 Apr 01;10(4): [PMID: 35448048]
  13. Int J Environ Res Public Health. 2019 Sep 30;16(19): [PMID: 31574897]
  14. Curr Opin Pediatr. 2016 Jun;28(3):407-12 [PMID: 27093354]
  15. Clin Microbiol Infect. 2015 Sep;21(9):827-33 [PMID: 25980355]
  16. Oncoscience. 2021 Aug 09;8:91-93 [PMID: 34386547]
  17. Front Oncol. 2022 Sep 13;12:977933 [PMID: 36176419]
  18. Korean J Pathol. 2014 Feb;48(1):24-9 [PMID: 24627691]
  19. Nat Commun. 2020 Jun 5;11(1):2841 [PMID: 32503989]
  20. Asia Pac J Oncol Nurs. 2023 Jul 31;10(9):100279 [PMID: 37661962]
  21. BMC Infect Dis. 2021 Jan 6;21(1):11 [PMID: 33407188]
  22. Cancer Causes Control. 2017 Nov;28(11):1333-1340 [PMID: 28948421]
  23. Int J Cancer. 2023 Jul 15;153(2):417-426 [PMID: 36943030]
  24. Papillomavirus Res. 2020 Dec;10:100203 [PMID: 32659510]
  25. Cancer. 2017 Jun 15;123(12):2219-2229 [PMID: 28346680]
  26. Oral Maxillofac Surg. 2014 Jun;18(2):165-72 [PMID: 23242943]
  27. Cancer Causes Control. 2016 Dec;27(12):1491-1498 [PMID: 27804058]
  28. Breast Dis. 2022;41(1):123-132 [PMID: 34744058]
  29. Viruses. 2021 Jun 08;13(6): [PMID: 34201028]
  30. Rev Bras Epidemiol. 2016 Oct-Dec;19(4):791-802 [PMID: 28146168]
  31. JNCI Cancer Spectr. 2020 Jun 05;4(5):pkaa047 [PMID: 33225205]
  32. Biomed Res Int. 2021 Nov 2;2021:7312611 [PMID: 34765678]
  33. Virol J. 2018 May 25;15(1):94 [PMID: 29801461]
  34. BMC Womens Health. 2023 May 3;23(1):216 [PMID: 37138261]
  35. Cancer Epidemiol Biomarkers Prev. 2024 Jan 31;: [PMID: 38294704]
  36. J Pediatr Health Care. 2018 Mar - Apr;32(2):119-132 [PMID: 28918994]
  37. Int J Environ Res Public Health. 2018 Oct 10;15(10): [PMID: 30309014]
  38. Pediatr Clin North Am. 2023 Apr;70(2):211-226 [PMID: 36841591]
  39. Vaccines (Basel). 2024 Jan 26;12(2): [PMID: 38400111]
  40. J Public Health Dent. 2018 Dec;78(1):17-24 [PMID: 28675452]
  41. Viruses. 2021 Jul 11;13(7): [PMID: 34372545]
  42. JAMA. 2023 Jun 20;329(23):2068-2085 [PMID: 37338873]
  43. Biosensors (Basel). 2019 Feb 14;9(1): [PMID: 30769890]
  44. PLoS One. 2021 Jun 10;16(6):e0253007 [PMID: 34111196]
  45. Viruses. 2021 Aug 26;13(9): [PMID: 34578274]
  46. Recent Results Cancer Res. 2021;217:157-195 [PMID: 33200366]
  47. Biochem Med (Zagreb). 2015 Jun 05;25(2):177-92 [PMID: 26110030]
  48. Papillomavirus Res. 2017 Dec;4:54-57 [PMID: 29179870]
  49. Cancers (Basel). 2023 Feb 08;15(4): [PMID: 36831439]
  50. Expert Rev Gastroenterol Hepatol. 2019 Jan;13(1):71-88 [PMID: 30791842]
  51. Sex Transm Dis. 2023 Sep 1;50(9):567-574 [PMID: 37195274]
  52. Gynecol Oncol. 2006 Apr;101(1):40-5 [PMID: 16256180]
  53. Gynecol Oncol. 2019 Jul;154(1):110-117 [PMID: 30982556]
  54. Cancers (Basel). 2023 Sep 10;15(18): [PMID: 37760471]
  55. Hum Vaccin Immunother. 2016 Jun 2;12(6):1454-68 [PMID: 26838681]
  56. Jpn J Clin Oncol. 2022 Oct 6;52(10):1242-1247 [PMID: 35938523]
  57. Adv Ther. 2022 Sep;39(9):3933-3956 [PMID: 35844007]
  58. BMC Cancer. 2021 Sep 30;21(1):1071 [PMID: 34592954]
  59. Vaccine. 2014 Mar 20;32(14):1595-601 [PMID: 24606637]
  60. Cancer Rep (Hoboken). 2021 Aug;4(4):e1350 [PMID: 33624444]
  61. BMC Cancer. 2018 Jan 30;18(1):112 [PMID: 29382323]
  62. Head Neck. 2020 Oct;42(10):2975-2984 [PMID: 32573035]
  63. J Med Virol. 2024 Feb;96(2):e29460 [PMID: 38348874]

Word Cloud

Created with Highcharts 10.0.0high-riskHPV52HPV58HPV=oralstrainsincludingsamplessalivahumanprevalenceamongclinicalscreeningresearchdemonstratedpapillomavirususedtotal9%adulttestedpositiveadditionpediatricdataPreviouscaninfectwiderangetissueswithincavityHigh-riskassociateddevelopmentprogressioncancerssquamouscellcarcinomasAlthoughmanystudiesexaminedHPV16HPV18farfewerassessedapprovedstudyprotocolidentify87biorepositoryQuantitativepolymerasechainreactionqPCRvalidatedprimersfacilitate4/458harbored2/4544%6/42143%5/42113/4271%demonstratepresenceoncogenicpatientdetailedlongitudinalmustconducteddeterminewhethermayincreasingdecreasingtimestronglysupportpublichealthpreventioneffortsknowledgeawarenessnine-valentvaccinecoveringadditionalScreeningHigh-RiskHumanPapillomavirusRevealsPediatricAdultPatientSalivaSamplessamplingcancer

Similar Articles

Cited By (1)